Table 4.

The increase in discounts due to a new indication price renegotiation

Category	New indications discount increase (Δ discount)a				p value
	N	Mean (%)	SD	Median (%)
Orphan	13	12.8	0.089	15.7	0.475
Not orphan	39	13.1	0.127	10.5
Rare disease	24	13.4	0.09	14.9	0.302
Not rare disease	28	12.7	0.139	8.0
Antineoplastic drugs (ATC: L01)	32	14.5	0.103	14.9	0.030
Other drugs	20	10.6	0.135	5.1
MEA applied	9	7.2	0.126	3.4	0.012
MEA not applied	43	14.2	0.113	14.4
Innovative	19	14.6	0.092	14.0	0.179
Not innovative	33	12.1	0.129	8.0
With registry	34	13.1	0.094	12.6	0.276
Without registry	18	12.7	0.154	3.3
Class A and A/PHTb	12	10.3	0.095	8.7	0.416
Class Hc	40	13.8	0.123	12.8
Overall	52	13.0	0.117	12.5	–

Bold p-values are significant

Italic values indicate the average value for all the sample (n = 52) (i.e. not clustered)

ATC Anatomical Therapeutic Chemical classification system, MEA Managed Entry Agreements, P&R price and reimbursement

^aΔ discount: difference between the discount in force before the new indication P&R and the discount in force after

^bClass A: Medicines reimbursed in all settings; Class A/PHT: Medicines reimbursed in all settings but directly distributed by health authorities if used outside hospitals

^cClass H: Medicines reimbursed only in the hospital setting